Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
Novocure Ltd (NVCR) is up more than +11% after the US FDA approved the company’s Optune Lua to treat metastatic non-small cell lung cancer in adults who have progressed on or after a platinum-based ...
ASML extends losses after cutting sales guidance, Nvidia stock rises, and third-quarter earnings at Morgan Stanley top ...